Form 4: Biohaven Director Receives Stock Option Grant

Director Michael Thomas Heffernan was granted 68,693 stock options in Biohaven Ltd. as part of standard compensation.

Summary

• Director Michael Thomas Heffernan received a grant of 68,693 stock options on April 28, 2026.
• The options have an exercise price of $9.61 per share.
• The options are set to expire on April 28, 2036.
• The grant is subject to a vesting schedule tied to the earlier of April 28, 2027, or the 2027 Annual Meeting of Shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in full on April 28, 2027, or the date of the 2027 Annual Meeting of Shareholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. pharmaceutical industry.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on April 28, 2027, or the 2027 Annual Meeting of Shareholders.

Key Dates

Keywords

Biohaven, BHVN, Director Compensation, Stock Options, Insider Transaction, SEC Form 4